SyntheX is expanding drug design into the “undruggable” space for the treatment of cancer and rare diseases. We implement an innovative platform for the accelerated discovery of new classes of therapeutics that target the Achilles’ heel of cancer cells in a highly specific and selective manner. At SyntheX, we are expanding the drug discovery space from active site inhibitors to protein-protein interaction modulators using our innovative screening technology.